acta2-optoα1AR-IRES-lacZ Strain Information Sheet
Common Name: acta2-optoα1AR-IRES-lacZ
CHROMusTM designation and lines available: R24:B6 Line 1
Jackson Stock number: Jax# 028346
Development: The rhodopsin based effector, optoα1AR which on activation generates the second messenger diacylglycerol/IP3, was inserted at the ATG site of the acta2 gene in the BAC RP23-370F21 (CHORI) through homologous recombination. The resulting recombinant BAC was injected into the male pronucleus of fertilized oocytes which were then implanted into pseudo pregnant females. Resulting offspring were screened for the presence of the transgene (founders). Colonies were established from each founder and tested for expression.
|# pups born||# founders||# expressers|
Description: The rhodopsin based effector, optoα1AR is expressed under control of the acta2 promoter, directing expression to smooth muscle cells in blood vessels, airways of the lung and gut. Expression may be present in other smooth muscle containing tissues which have not been examined. An internal ribosome entry site (IRES) allows for co-expression of lacZ as a visual indicator of expression patterns.
|Expected size of product:||478bp|
94oC 3 minutes
So as to appropriately acknowledge and credit the scientists who have produced the acta2-optoα1AR-IRES-lacZ mouse strain, it is expected that you will include these individuals in any publication that is submitted prior to the initial publication of this line from the Kotlikoff laboratory.
Acknowledgement: Please inform us of any publications resulting from the use of this mouse and use the following statement to acknowledge their development:
The mouse strain acta2-optoα1AR-IRES-lacZ was developed by CHROMusTM which is supported by the National Heart Lung Blood Institute of the National Institute of Health under award number R24HL120847.